Among patients with colon cancer, gender played a pivotal role in genetic polymorphisms in drug-associated clinically actionable genes (XPD, MTHFR, and ECCR1 genes), leading to different toxic responses to chemotherapies 55. This evidence concerns the gene ERCC2 and malignant colon neoplasm.